Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer.
Eighteen patients with either metastatic or locally advanced pancreatic carcinoma were treated with intravenous infusion of Pirarubicin 50 mg/m2/day every 3 weeks. Seventeen patients were evaluable for response. One had minor response, 5 had stable disease, and 11 had progression of disease. Hematological toxicity was moderate, leading to a dose reduction in only 1 patient; there was no clinical cardiac toxicity. We conclude that Pirarubicin used with this dosage and schedule has no activity in advanced pancreatic carcinoma.
Laboratoire Roger Bellon Neully Sur Seine, France.
M
M
Mahjoubi
P
P
Rougier
J
J
Oliviera
P
P
Herait
J M
JM
Tigaud
J P
JP
Droz
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C027260:pirarubicin